Opaleye Management Inc. - 14 Aug 2026 Form 4 Insider Report for Grace Therapeutics, Inc. (GRCE)

Reporting relationship: 10%+ Owner
Issuer ticker: GRCE
Reported as of: 14 Aug 2026
Net transaction value: +$24,206
SEC form: 4
Accepted by SEC: 19 Aug 2026, 07:44:39 UTC
Prior SEC filing: 14 Aug 2026
Source filing: View source filing
Reporting owner signature: Opaleye Management, Inc., By: /s/ James Silverman, President

Key filing fact

Opaleye Management Inc. filed Form 4 for Grace Therapeutics, Inc. (GRCE) on 19 Aug 2026.

Key facts

This page summarizes Opaleye Management Inc.'s Form 4 filing for Grace Therapeutics, Inc. (GRCE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Aug 2026, 07:44.

Change

Previous filing in this sequence was filed on 14 Aug 2026.
Current net transaction value: +$24,206.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001595855 Primary reporting owner

Opaleye Management Inc.

Relationship: 10%+ Owner
Address: ONE BOSTON PLACE, 26TH FLOOR, BOSTON
Signature: Opaleye Management, Inc., By: /s/ James Silverman, President
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRCE transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $24,206
Shares: +11,608
Change %: +0.42%
Price: $2.09
Shares after: 2,760,000
Date: 14 Aug 2026
Ownership: By Opaleye, L.P.
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.

Footnote F2

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

Footnote F3

Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.